Dark

Check out our Dark Pool Levels

NURO
NeuroMetrix, Inc. Common Stock
stock NASDAQ

Inactive

May 1, 2025

4.58USD+5.046%(+0.22)35,587

Pre-market

0.00USD-100.000%(-4.36)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 27, 2022

07:18AM EST NeuroMetrix Q4 Sales $1.82M Up From $1.81M YoY Benzinga

07:00AM EST NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices. GlobeNewswire Inc

04:37AM EST Earnings Scheduled For January 27, 2022 Benzinga

Jan 20, 2022

12:11PM EST NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of the market on January 27, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on January 27, 2022 to discuss its financial results as well as business developments affecting the Company. GlobeNewswire Inc

Jan 18, 2022

02:33PM EST Mid-Afternoon Market Update: Dow Dips 500 Points; NeuroMetrix Shares Spike Higher Benzinga

12:09PM EST Mid-Day Market Update: Nasdaq Tumbles 250 Points; Activision Blizzard Shares Jump Benzinga

10:25AM EST Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Earnings Miss Views Benzinga

09:08AM EST NeuroMetrix Reports Received FDA Breakthrough Device Designation For Treatment Of Chronic Chemo Induced Peripheral Neuropathy With Its Wearable Neurostimulation Technology Benzinga

09:00AM EST NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell technology has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for reducing moderate to severe symptoms of chemotherapy induced peripheral neuropathy that have persisted for at least 6-months following the end of chemotherapy. GlobeNewswire Inc

Jan 10, 2022

09:00AM EST NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as GlobeNewswire Inc

Jan 5, 2022

09:00AM EST NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022 GlobeNewswire Inc

Dec 7, 2021

01:36PM EST NeuroMetrix Granted U.S. Patent Titled 'Detecting cutaneous electrode peeling using electrode-skin impedance' Benzinga

Oct 21, 2021

12:11PM EDT The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO Benzinga

12:11PM EDT NeuroMetrix Q3 EPS $(0.12) Down From $(0.07) YoY, Sales $2.06M Up From $2.04M YoY Benzinga

12:11PM EDT Earnings Scheduled For October 21, 2021 Benzinga

07:00AM EDT NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. GlobeNewswire Inc

Oct 20, 2021

09:00AM EDT NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, GlobeNewswire Inc

Oct 14, 2021

09:00AM EDT NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 third quarter financial results before the opening of the market on October 21, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on October 21, 2021 to discuss its financial results as well as business developments affecting the Company. GlobeNewswire Inc

Oct 12, 2021

09:55AM EDT Chinese AI Research and Business is Booming, but America is Still King Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

06:30AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.05 A.M. EDT). RTTNews

Oct 6, 2021

10:10PM EDT NeuroMetrix Inc. (NURO) said that it has submitted a De Novo request to the U.S. Food and Drug Administration for Quell Wearable Neuromodulation Device as a prescription treatment for the symptoms of fibromyalgia in adults. The company received FDA Breakthrough Designation for this indication in July. RTTNews

06:42PM EDT NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a prescription treatment for the symptoms of fibromyalgia in adults. The Company received FDA Breakthrough Designation for this indication in July. GlobeNewswire Inc

Oct 5, 2021

09:00AM EDT NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner. GlobeNewswire Inc

Sep 23, 2021

11:03AM EDT Shares of healthcare company NeuroMetrix, Inc. (NURO) are up more than 15% in the morning trade on Thursday at $13.95. RTTNews

Aug 30, 2021

05:51AM EDT The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.36 A.M. EDT). RTTNews

Aug 27, 2021

12:59PM EDT What's Going On With NeuroMetrix Shares Today? Benzinga

10:33AM EDT Shares of NeuroMetrix Inc. (NURO) are surging nearly 40% on Friday morning driven by meme-stock investors. RTTNews

10:10AM EDT Mid-Morning Market Update: Markets Open Higher; Big Lots Reports Downbeat Profit Benzinga

06:44AM EDT The following are some of the stocks making big moves in Friday's pre-market trading (as of 6.17 A.M. EDT). RTTNews

Aug 13, 2021

08:05AM EDT NeuroMetrix Filed Prospectus Supplement With Securities And Exchange Commission To Register Offer, Sale Of $14M Of Co's Common Stock Benzinga

Jul 26, 2021

11:24AM EDT NeuroMetrix Receives Notice Of Allowance For U.S. Patent Application Titled 'DETECTING CUTANEOUS ELECTRODE PEELING USING ELECTRODE-SKIN IMPEDANCE' Benzinga

09:02AM EDT NeuroMetrix Announces Peer-Reviewed Publication Of Randomized Controlled Trial Of Its Wearable Neurostimulation Technology For Treatment Of Fibromyalgia Benzinga

09:00AM EDT NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research. The article is available online at the journal website. GlobeNewswire Inc

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 22, 2021

11:34AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO Benzinga

07:12AM EDT NeuroMetrix Q2 Sales $2.20M Up From $1.36M YoY Benzinga

07:00AM EDT NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. GlobeNewswire Inc

04:02AM EDT Earnings Scheduled For July 22, 2021 Benzinga

Jul 21, 2021

12:15PM EDT Mid-Day Market Update: Crude Oil Up 4%; Chembio Diagnostics Shares Spike Higher Benzinga

10:47AM EDT Mid-Morning Market Update: Markets Open Higher; Coca-Cola Tops Q2 Views Benzinga

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 20, 2021

02:56PM EDT Mid-Afternoon Market Update: Dow Jumps Over 600 Points; NeuroMetrix Shares Spike Higher Benzinga

12:10PM EDT Mid-Day Market Update: HCA Healthcare Surges On Upbeat Results; Ardelyx Shares Slide Benzinga

11:04AM EDT NeuroMetrix Stock Surges As Its Nerve Stimulator Scores FDA Breakthrough Designation For Fibromyalgia Benzinga

10:25AM EDT NeuroMetrix, Inc. (NURO) shares are gaining on Tuesday morning as the company said it's Quell device has received breakthrough designation from the U.S. FDA for treating the symptoms of fibromyalgia in adults. Fibromyalgia is a common form of chronic pain that is also accompanied by fatigue, sleep, cognitive and mood disturbances. RTTNews

09:01AM EDT NeuroMetrix Says Receives FDA Breakthrough Device Designation For Treatment Of Fibromyalgia With Its Wearable Neurostimulation Technology Benzinga

09:00AM EDT NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for treating the symptoms of fibromyalgia in adults. GlobeNewswire Inc

Jul 15, 2021

09:02AM EDT NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 second quarter financial results before the opening of the market on July 22, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on July 22, 2021 to discuss its financial results as well as business developments affecting the Company. GlobeNewswire Inc

Jul 13, 2021

10:14AM EDT NeuroMetrix Granted U.S. Patent Titled 'Apparatus and method for the automated control of transcutaneous electrical nerve stimulation based on current and forecasted weather conditions' Benzinga

Jun 30, 2021

04:29PM EDT NeuroMetrix Entered Termination Agreement With GSK Consumer Healthcare S.A. In Which Co. Terminated Development And Services Agreement For Quell; GASK Transferred To NeuroMetrix All Rights, Title And Interest In Quell Related To Markets Outside US Benzinga

Jun 15, 2021

09:03AM EDT NeuroMetrix Reports Quell Technology Is To Be Evaluated For Neuromyelitis Optica Spectrum Disorder In A Randomized Controlled Trial Benzinga

09:00AM EDT NeuroMetrix Reports that Quell Technology is to be GlobeNewswire Inc

Jun 9, 2021

11:21AM EDT NeuroMetrix's Nerve Stimulator Shows Mixed Outcomes In Fibromyalgia Trial Benzinga

08:09AM EDT NeuroMetrix To Present Results From Quell Trial At Two Upcoming Pain Medicine Conferences Benzinga

08:00AM EDT NeuroMetrix, Inc. (Nasdaq: NURO) today reported that top-line results from a randomized controlled trial of Quell in patients with fibromyalgia will be presented at two upcoming pain medicine conferences. GlobeNewswire Inc

Apr 22, 2021

12:21PM EDT Earnings Scheduled For April 22, 2021 Benzinga

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

07:26AM EDT NeuroMetrix Q1 EPS $(0.02) Up From $(0.50) YoY, Sales $2.15M Down From $2.17M YoY Benzinga

07:00AM EDT NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. GlobeNewswire Inc

04:01AM EDT Earnings Scheduled For April 22, 2021 Benzinga

Apr 15, 2021

01:00PM EDT NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 first quarter financial results before the opening of the market on April 22, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on April 22, 2021 to discuss its financial results as well as business developments affecting the Company. GlobeNewswire Inc

Mar 3, 2021

11:18AM EST NeuroMetrix Shares Spike Higher; Co Received Notice Of Allowance For U.S. Patent Application Titled 'APPARATUS AND METHOD FOR THE AUTOMATED CONTROL OF TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION BASED ON CURRENT AND FORECASTED WEATHER CONDITIONS' Benzinga

Jan 28, 2021

07:16AM EST NeuroMetrix Q4 Sales $1.81M Up From $1.71M YoY Benzinga

07:00AM EST NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020. The Company is focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. GlobeNewswire Inc

04:08AM EST Earnings Scheduled For January 28, 2021 Benzinga

Jan 22, 2021

11:05AM EST NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of the market on January 28, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on January 28, 2021 to discuss its financial results as well as business developments affecting the Company. GlobeNewswire Inc

Dec 15, 2020

09:55AM EST NeuroMetrix Shares Up 6%; Co Granted U.S. Patent Titled 'Transcutaneous electrical nerve stimulation using novel unbalanced biphasic waveform and novel electrode arrangement' Benzinga

Dec 8, 2020

10:29AM EST Shares of NeuroMetrix, Inc. (NURO) are currently surging over 100% despite no stock related news. RTTNews

10:16AM EST Mid-Morning Market Update: Markets Edge Lower; AutoZone Earnings Top Estimates Benzinga

Oct 22, 2020

07:52AM EDT The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat Benzinga

07:07AM EDT NeuroMetrix Q3 Sales $2.04M Down From $2.09M YoY Benzinga

07:00AM EDT NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020. The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health conditions. GlobeNewswire Inc

04:38AM EDT Earnings Scheduled For October 22, 2020 Benzinga

Oct 21, 2020

01:45PM EDT NeuroMetrix Received Notice Of Allowance For U.S. Patent Titled 'APPARATUS AND METHOD FOR BUTTON-FREE CONTROL OF A WEARABLE TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR USING INTERACTIVE GESTURES AND OTHER MEANS' Benzinga

Oct 15, 2020

11:00AM EDT NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on October 22, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on October 22, 2020 to discuss its financial results as well as business developments affecting the Company. GlobeNewswire Inc

Sep 22, 2020

07:17AM EDT NeuroMetrix Announces Launch Of The Quell Watch App RTTNews

07:01AM EDT NeuroMetrix Launches Quell Pain Relief Device App For Apple Watch Benzinga

07:00AM EDT NeuroMetrix, Inc.(Nasdaq: NURO) today reported the launch of the Quell Watch App, now available for download from the Apple App store. GlobeNewswire Inc

Sep 21, 2020

01:03PM EDT NuroMetrix Shares Spike; Co Announces Issuance Of New U.S. Patent For Quell Wearable Technology Benzinga

01:00PM EDT NeuroMetrix, Inc.(Nasdaq: NURO) announced today that the U.S. Patent and Trademark Officewill issue on September 22, 2020 U.S. Patent No. 10,780,269 titled Apparatus and Method for Relieving Pain Using Transcutaneous Electrical Nerve Stimulation." GlobeNewswire Inc

Sep 17, 2020

04:47PM EDT Neurometrix Issued U.S. Patent Titled 'Apparatus and method for relieving pain using transcutaneous electrical nerve stimulation.' Benzinga

Sep 4, 2020

07:00AM EDT NeuroMetrix, Inc.(Nasdaq: NURO) today reported that it will present a scientific poster at thePAINWeek 2020 Live Virtual Conference to be heldSeptember 11 - 13. PAINWeek is the preferred resource in the U.S. for frontline practitioners treating acute and chronic pain. GlobeNewswire Inc

Sep 1, 2020

01:01PM EDT NeuroMetrix Reports Publication Of Study Validating DPNCheck Staging Of Diabetic Peripheral Neuropathy Severity Benzinga

01:00PM EDT NeuroMetrix Reports Publication of Study Validating GlobeNewswire Inc

Aug 25, 2020

10:20AM EDT NeuroMetrix Granted Canadian Patent Titled 'APPARATUS AND METHOD FOR THE AUTOMATED MEASUREMENT OF SURAL NERVE CONDUCTION VELOCITY AND AMPLITUDE' Benzinga

Aug 20, 2020

02:12PM EDT NeuroMetrix Reports That Quell To Be Evaluated For Chemotherapy-Induced Peripheral Neuropathy In NIH-Funded Clinical Trial Benzinga

02:12PM EDT NeuroMetrix Reports that Quell is to be Evaluated for GlobeNewswire Inc

Aug 10, 2020

10:00AM EDT NeuroMetrix, Inc.(Nasdaq: NURO) published an infographic on chronic knee pain (available here) and provided an update on how Quell technology addresses knee pain. GlobeNewswire Inc

Jul 23, 2020

07:03AM EDT NeuroMetrix Q2 Net Loss $851.9K vs $3.36M In Same Qtr. Last Year, Sales $1.36M Down From $2.35M YoY Benzinga

07:00AM EDT NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020. The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health conditions. GlobeNewswire Inc

04:30AM EDT Earnings Scheduled For July 23, 2020 Benzinga

Jul 16, 2020

03:15PM EDT NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the market on Thursday, July 23, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on July 23, 2020 to discuss its financial results as well as business developments affecting the Company. GlobeNewswire Inc

Share